Jaguar Health Inc (NASDAQ: JAGX)’s stock price has gone decline by -6.46 in comparison to its previous close of 5.57, however, the company has experienced a 8.77% increase in its stock price over the last five trading days. accessnewswire.com reported 2025-04-08 that Gelclair ® is the company’s third commercialized prescription product Oral mucositis, also called “chemo mouth,” a painful inflammation of the mouth’s mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Napo’s core target patient audiences for Gelclair are head and neck cancer patients and bone marrow transplant patients SAN FRANCISCO, CA / ACCESS Newswire / April 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar”) today announced that Jaguar family company Napo Pharmaceuticals (“Napo”) is exhibiting at the 50th anniversary Oncology Nursing Society (ONS) Congress taking place April 9-13, 2025 in Denver, Colorado as part of ongoing commercial activities for Gelclair. “We have expanded our footprint beyond HIV-related supportive care to include cancer-related supportive care, and our recent in-licensing of the FDA-approved oral mucositis product Gelclair is a first building block,” said Lisa Conte, Jaguar’s president and CEO.
Is It Worth Investing in Jaguar Health Inc (NASDAQ: JAGX) Right Now?
Additionally, the 36-month beta value for JAGX is 1.09. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for JAGX is 0.56M and currently, short sellers hold a 9.12% ratio of that float. The average trading volume of JAGX on April 15, 2025 was 31.30K shares.
JAGX’s Market Performance
JAGX’s stock has seen a 8.77% increase for the week, with a -53.17% drop in the past month and a -77.50% fall in the past quarter. The volatility ratio for the week is 25.80%, and the volatility levels for the past 30 days are at 17.22% for Jaguar Health Inc The simple moving average for the past 20 days is -0.76% for JAGX’s stock, with a -82.42% simple moving average for the past 200 days.
Analysts’ Opinion of JAGX
Many brokerage firms have already submitted their reports for JAGX stocks, with Cantor Fitzgerald repeating the rating for JAGX by listing it as a “Overweight.” The predicted price for JAGX in the upcoming period, according to Cantor Fitzgerald is $5 based on the research report published on July 07, 2021 of the previous year 2021.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see JAGX reach a price target of $2. The rating they have provided for JAGX stocks is “Buy” according to the report published on July 11th, 2017.
JAGX Trading at -59.22% from the 50-Day Moving Average
After a stumble in the market that brought JAGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.04% of loss for the given period.
Volatility was left at 17.22%, however, over the last 30 days, the volatility rate increased by 25.80%, as shares sank -55.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -76.44% lower at present.
During the last 5 trading sessions, JAGX rose by +8.77%, which changed the moving average for the period of 200-days by -94.60% in comparison to the 20-day moving average, which settled at $5.25. In addition, Jaguar Health Inc saw -79.37% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for JAGX
Current profitability levels for the company are sitting at:
- -2.64 for the present operating margin
- 0.78 for the gross margin
The net margin for Jaguar Health Inc stands at -3.29. The total capital return value is set at -0.91. Equity return is now at value -522.60, with -73.89 for asset returns.
Based on Jaguar Health Inc (JAGX), the company’s capital structure generated 0.83 points at debt to capital in total, while cash flow to debt ratio is standing at -0.8. The debt to equity ratio resting at 5.01. The interest coverage ratio of the stock is -50.46.
Currently, EBITDA for the company is -36.66 million with net debt to EBITDA at -0.77. When we switch over and look at the enterprise to sales, we see a ratio of 2.74. The receivables turnover for the company is 7.1for trailing twelve months and the total asset turnover is 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.63.
Conclusion
In conclusion, Jaguar Health Inc (JAGX) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
